Global Epidermolysis Bullosa Therapeutics Market Growth 2025-2031

January 2025 | 115 pages | ID: G4FD14A7E168EN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Epidermolysis Bullosa Therapeutics market size is predicted to grow from US$ 1749 million in 2025 to US$ 2338 million in 2031; it is expected to grow at a CAGR of 5.0% from 2025 to 2031.

United States market for Epidermolysis Bullosa Therapeutics is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Epidermolysis Bullosa Therapeutics is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Epidermolysis Bullosa Therapeutics is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Epidermolysis Bullosa Therapeutics players cover Birken AG, Fibrocell Science, Inc., GlaxoSmithKline Plc, InMed Pharmaceuticals Inc., Karus Therapeutics Limited, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the “Epidermolysis Bullosa Therapeutics Industry Forecast” looks at past sales and reviews total world Epidermolysis Bullosa Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Epidermolysis Bullosa Therapeutics sales for 2025 through 2031. With Epidermolysis Bullosa Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Epidermolysis Bullosa Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Epidermolysis Bullosa Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Epidermolysis Bullosa Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Epidermolysis Bullosa Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Epidermolysis Bullosa Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Epidermolysis Bullosa Therapeutics.

This report presents a comprehensive overview, market shares, and growth opportunities of Epidermolysis Bullosa Therapeutics market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• EB-201
• FCX-007
• ICX-RHY
• INM-750
• Others

Segmentation by Application:

• Clinic
• Hospital
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Birken AG
• Fibrocell Science, Inc.
• GlaxoSmithKline Plc
• InMed Pharmaceuticals Inc.
• Karus Therapeutics Limited
• ProQR Therapeutics N.V.
• RegeneRx Biopharmaceuticals, Inc.
• Scioderm, Inc.
• Stratatech Corporation
• TWi Pharmaceuticals, Inc.
• WAVE Life Sciences Ltd.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Epidermolysis Bullosa Therapeutics market?

What factors are driving Epidermolysis Bullosa Therapeutics market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Epidermolysis Bullosa Therapeutics market opportunities vary by end market size?

How does Epidermolysis Bullosa Therapeutics break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Epidermolysis Bullosa Therapeutics Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Country/Region, 2020, 2024 & 2031
2.2 Epidermolysis Bullosa Therapeutics Segment by Type
  2.2.1 EB-201
  2.2.2 FCX-007
  2.2.3 ICX-RHY
  2.2.4 INM-750
  2.2.5 Others
2.3 Epidermolysis Bullosa Therapeutics Sales by Type
  2.3.1 Global Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2020-2025)
  2.3.2 Global Epidermolysis Bullosa Therapeutics Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Epidermolysis Bullosa Therapeutics Sale Price by Type (2020-2025)
2.4 Epidermolysis Bullosa Therapeutics Segment by Application
  2.4.1 Clinic
  2.4.2 Hospital
  2.4.3 Others
2.5 Epidermolysis Bullosa Therapeutics Sales by Application
  2.5.1 Global Epidermolysis Bullosa Therapeutics Sale Market Share by Application (2020-2025)
  2.5.2 Global Epidermolysis Bullosa Therapeutics Revenue and Market Share by Application (2020-2025)
  2.5.3 Global Epidermolysis Bullosa Therapeutics Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Epidermolysis Bullosa Therapeutics Breakdown Data by Company
  3.1.1 Global Epidermolysis Bullosa Therapeutics Annual Sales by Company (2020-2025)
  3.1.2 Global Epidermolysis Bullosa Therapeutics Sales Market Share by Company (2020-2025)
3.2 Global Epidermolysis Bullosa Therapeutics Annual Revenue by Company (2020-2025)
  3.2.1 Global Epidermolysis Bullosa Therapeutics Revenue by Company (2020-2025)
  3.2.2 Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Company (2020-2025)
3.3 Global Epidermolysis Bullosa Therapeutics Sale Price by Company
3.4 Key Manufacturers Epidermolysis Bullosa Therapeutics Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Epidermolysis Bullosa Therapeutics Product Location Distribution
  3.4.2 Players Epidermolysis Bullosa Therapeutics Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR EPIDERMOLYSIS BULLOSA THERAPEUTICS BY GEOGRAPHIC REGION

4.1 World Historic Epidermolysis Bullosa Therapeutics Market Size by Geographic Region (2020-2025)
  4.1.1 Global Epidermolysis Bullosa Therapeutics Annual Sales by Geographic Region (2020-2025)
  4.1.2 Global Epidermolysis Bullosa Therapeutics Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Epidermolysis Bullosa Therapeutics Market Size by Country/Region (2020-2025)
  4.2.1 Global Epidermolysis Bullosa Therapeutics Annual Sales by Country/Region (2020-2025)
  4.2.2 Global Epidermolysis Bullosa Therapeutics Annual Revenue by Country/Region (2020-2025)
4.3 Americas Epidermolysis Bullosa Therapeutics Sales Growth
4.4 APAC Epidermolysis Bullosa Therapeutics Sales Growth
4.5 Europe Epidermolysis Bullosa Therapeutics Sales Growth
4.6 Middle East & Africa Epidermolysis Bullosa Therapeutics Sales Growth

5 AMERICAS

5.1 Americas Epidermolysis Bullosa Therapeutics Sales by Country
  5.1.1 Americas Epidermolysis Bullosa Therapeutics Sales by Country (2020-2025)
  5.1.2 Americas Epidermolysis Bullosa Therapeutics Revenue by Country (2020-2025)
5.2 Americas Epidermolysis Bullosa Therapeutics Sales by Type (2020-2025)
5.3 Americas Epidermolysis Bullosa Therapeutics Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Epidermolysis Bullosa Therapeutics Sales by Region
  6.1.1 APAC Epidermolysis Bullosa Therapeutics Sales by Region (2020-2025)
  6.1.2 APAC Epidermolysis Bullosa Therapeutics Revenue by Region (2020-2025)
6.2 APAC Epidermolysis Bullosa Therapeutics Sales by Type (2020-2025)
6.3 APAC Epidermolysis Bullosa Therapeutics Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Epidermolysis Bullosa Therapeutics by Country
  7.1.1 Europe Epidermolysis Bullosa Therapeutics Sales by Country (2020-2025)
  7.1.2 Europe Epidermolysis Bullosa Therapeutics Revenue by Country (2020-2025)
7.2 Europe Epidermolysis Bullosa Therapeutics Sales by Type (2020-2025)
7.3 Europe Epidermolysis Bullosa Therapeutics Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Epidermolysis Bullosa Therapeutics by Country
  8.1.1 Middle East & Africa Epidermolysis Bullosa Therapeutics Sales by Country (2020-2025)
  8.1.2 Middle East & Africa Epidermolysis Bullosa Therapeutics Revenue by Country (2020-2025)
8.2 Middle East & Africa Epidermolysis Bullosa Therapeutics Sales by Type (2020-2025)
8.3 Middle East & Africa Epidermolysis Bullosa Therapeutics Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Epidermolysis Bullosa Therapeutics
10.3 Manufacturing Process Analysis of Epidermolysis Bullosa Therapeutics
10.4 Industry Chain Structure of Epidermolysis Bullosa Therapeutics

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Epidermolysis Bullosa Therapeutics Distributors
11.3 Epidermolysis Bullosa Therapeutics Customer

12 WORLD FORECAST REVIEW FOR EPIDERMOLYSIS BULLOSA THERAPEUTICS BY GEOGRAPHIC REGION

12.1 Global Epidermolysis Bullosa Therapeutics Market Size Forecast by Region
  12.1.1 Global Epidermolysis Bullosa Therapeutics Forecast by Region (2026-2031)
  12.1.2 Global Epidermolysis Bullosa Therapeutics Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Epidermolysis Bullosa Therapeutics Forecast by Type (2026-2031)
12.7 Global Epidermolysis Bullosa Therapeutics Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Birken AG
  13.1.1 Birken AG Company Information
  13.1.2 Birken AG Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications
  13.1.3 Birken AG Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 Birken AG Main Business Overview
  13.1.5 Birken AG Latest Developments
13.2 Fibrocell Science, Inc.
  13.2.1 Fibrocell Science, Inc. Company Information
  13.2.2 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications
  13.2.3 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)
  13.2.4 Fibrocell Science, Inc. Main Business Overview
  13.2.5 Fibrocell Science, Inc. Latest Developments
13.3 GlaxoSmithKline Plc
  13.3.1 GlaxoSmithKline Plc Company Information
  13.3.2 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications
  13.3.3 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)
  13.3.4 GlaxoSmithKline Plc Main Business Overview
  13.3.5 GlaxoSmithKline Plc Latest Developments
13.4 InMed Pharmaceuticals Inc.
  13.4.1 InMed Pharmaceuticals Inc. Company Information
  13.4.2 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications
  13.4.3 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)
  13.4.4 InMed Pharmaceuticals Inc. Main Business Overview
  13.4.5 InMed Pharmaceuticals Inc. Latest Developments
13.5 Karus Therapeutics Limited
  13.5.1 Karus Therapeutics Limited Company Information
  13.5.2 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications
  13.5.3 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)
  13.5.4 Karus Therapeutics Limited Main Business Overview
  13.5.5 Karus Therapeutics Limited Latest Developments
13.6 ProQR Therapeutics N.V.
  13.6.1 ProQR Therapeutics N.V. Company Information
  13.6.2 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications
  13.6.3 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)
  13.6.4 ProQR Therapeutics N.V. Main Business Overview
  13.6.5 ProQR Therapeutics N.V. Latest Developments
13.7 RegeneRx Biopharmaceuticals, Inc.
  13.7.1 RegeneRx Biopharmaceuticals, Inc. Company Information
  13.7.2 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications
  13.7.3 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)
  13.7.4 RegeneRx Biopharmaceuticals, Inc. Main Business Overview
  13.7.5 RegeneRx Biopharmaceuticals, Inc. Latest Developments
13.8 Scioderm, Inc.
  13.8.1 Scioderm, Inc. Company Information
  13.8.2 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications
  13.8.3 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)
  13.8.4 Scioderm, Inc. Main Business Overview
  13.8.5 Scioderm, Inc. Latest Developments
13.9 Stratatech Corporation
  13.9.1 Stratatech Corporation Company Information
  13.9.2 Stratatech Corporation Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications
  13.9.3 Stratatech Corporation Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)
  13.9.4 Stratatech Corporation Main Business Overview
  13.9.5 Stratatech Corporation Latest Developments
13.10 TWi Pharmaceuticals, Inc.
  13.10.1 TWi Pharmaceuticals, Inc. Company Information
  13.10.2 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications
  13.10.3 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)
  13.10.4 TWi Pharmaceuticals, Inc. Main Business Overview
  13.10.5 TWi Pharmaceuticals, Inc. Latest Developments
13.11 WAVE Life Sciences Ltd.
  13.11.1 WAVE Life Sciences Ltd. Company Information
  13.11.2 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications
  13.11.3 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2020-2025)
  13.11.4 WAVE Life Sciences Ltd. Main Business Overview
  13.11.5 WAVE Life Sciences Ltd. Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION


LIST OFTABLES

Table 1. Epidermolysis BullosaTherapeutics Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Epidermolysis BullosaTherapeutics Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of EB-201
Table 4. Major Players ofFCX-007
Table 5. Major Players of ICX-RHY
Table 6. Major Players of INM-750
Table 7. Major Players of Others
Table 8. Global Epidermolysis BullosaTherapeutics Sales byType (2020-2025) & (K Pcs)
Table 9. Global Epidermolysis BullosaTherapeutics Sales Market Share byType (2020-2025)
Table 10. Global Epidermolysis BullosaTherapeutics Revenue byType (2020-2025) & ($ million)
Table 11. Global Epidermolysis BullosaTherapeutics Revenue Market Share byType (2020-2025)
Table 12. Global Epidermolysis BullosaTherapeutics Sale Price byType (2020-2025) & (USD/Pcs)
Table 13. Global Epidermolysis BullosaTherapeutics Sale by Application (2020-2025) & (K Pcs)
Table 14. Global Epidermolysis BullosaTherapeutics Sale Market Share by Application (2020-2025)
Table 15. Global Epidermolysis BullosaTherapeutics Revenue by Application (2020-2025) & ($ million)
Table 16. Global Epidermolysis BullosaTherapeutics Revenue Market Share by Application (2020-2025)
Table 17. Global Epidermolysis BullosaTherapeutics Sale Price by Application (2020-2025) & (USD/Pcs)
Table 18. Global Epidermolysis BullosaTherapeutics Sales by Company (2020-2025) & (K Pcs)
Table 19. Global Epidermolysis BullosaTherapeutics Sales Market Share by Company (2020-2025)
Table 20. Global Epidermolysis BullosaTherapeutics Revenue by Company (2020-2025) & ($ millions)
Table 21. Global Epidermolysis BullosaTherapeutics Revenue Market Share by Company (2020-2025)
Table 22. Global Epidermolysis BullosaTherapeutics Sale Price by Company (2020-2025) & (USD/Pcs)
Table 23. Key Manufacturers Epidermolysis BullosaTherapeutics Producing Area Distribution and Sales Area
Table 24. Players Epidermolysis BullosaTherapeutics Products Offered
Table 25. Epidermolysis BullosaTherapeutics Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Epidermolysis BullosaTherapeutics Sales by Geographic Region (2020-2025) & (K Pcs)
Table 29. Global Epidermolysis BullosaTherapeutics Sales Market Share Geographic Region (2020-2025)
Table 30. Global Epidermolysis BullosaTherapeutics Revenue by Geographic Region (2020-2025) & ($ millions)
Table 31. Global Epidermolysis BullosaTherapeutics Revenue Market Share by Geographic Region (2020-2025)
Table 32. Global Epidermolysis BullosaTherapeutics Sales by Country/Region (2020-2025) & (K Pcs)
Table 33. Global Epidermolysis BullosaTherapeutics Sales Market Share by Country/Region (2020-2025)
Table 34. Global Epidermolysis BullosaTherapeutics Revenue by Country/Region (2020-2025) & ($ millions)
Table 35. Global Epidermolysis BullosaTherapeutics Revenue Market Share by Country/Region (2020-2025)
Table 36. Americas Epidermolysis BullosaTherapeutics Sales by Country (2020-2025) & (K Pcs)
Table 37. Americas Epidermolysis BullosaTherapeutics Sales Market Share by Country (2020-2025)
Table 38. Americas Epidermolysis BullosaTherapeutics Revenue by Country (2020-2025) & ($ millions)
Table 39. Americas Epidermolysis BullosaTherapeutics Sales byType (2020-2025) & (K Pcs)
Table 40. Americas Epidermolysis BullosaTherapeutics Sales by Application (2020-2025) & (K Pcs)
Table 41. APAC Epidermolysis BullosaTherapeutics Sales by Region (2020-2025) & (K Pcs)
Table 42. APAC Epidermolysis BullosaTherapeutics Sales Market Share by Region (2020-2025)
Table 43. APAC Epidermolysis BullosaTherapeutics Revenue by Region (2020-2025) & ($ millions)
Table 44. APAC Epidermolysis BullosaTherapeutics Sales byType (2020-2025) & (K Pcs)
Table 45. APAC Epidermolysis BullosaTherapeutics Sales by Application (2020-2025) & (K Pcs)
Table 46. Europe Epidermolysis BullosaTherapeutics Sales by Country (2020-2025) & (K Pcs)
Table 47. Europe Epidermolysis BullosaTherapeutics Revenue by Country (2020-2025) & ($ millions)
Table 48. Europe Epidermolysis BullosaTherapeutics Sales byType (2020-2025) & (K Pcs)
Table 49. Europe Epidermolysis BullosaTherapeutics Sales by Application (2020-2025) & (K Pcs)
Table 50. Middle East & Africa Epidermolysis BullosaTherapeutics Sales by Country (2020-2025) & (K Pcs)
Table 51. Middle East & Africa Epidermolysis BullosaTherapeutics Revenue Market Share by Country (2020-2025)
Table 52. Middle East & Africa Epidermolysis BullosaTherapeutics Sales byType (2020-2025) & (K Pcs)
Table 53. Middle East & Africa Epidermolysis BullosaTherapeutics Sales by Application (2020-2025) & (K Pcs)
Table 54. Key Market Drivers & Growth Opportunities of Epidermolysis BullosaTherapeutics
Table 55. Key Market Challenges & Risks of Epidermolysis BullosaTherapeutics
Table 56. Key IndustryTrends of Epidermolysis BullosaTherapeutics
Table 57. Epidermolysis BullosaTherapeutics Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Epidermolysis BullosaTherapeutics Distributors List
Table 60. Epidermolysis BullosaTherapeutics Customer List
Table 61. Global Epidermolysis BullosaTherapeutics SalesForecast by Region (2026-2031) & (K Pcs)
Table 62. Global Epidermolysis BullosaTherapeutics RevenueForecast by Region (2026-2031) & ($ millions)
Table 63. Americas Epidermolysis BullosaTherapeutics SalesForecast by Country (2026-2031) & (K Pcs)
Table 64. Americas Epidermolysis BullosaTherapeutics Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 65. APAC Epidermolysis BullosaTherapeutics SalesForecast by Region (2026-2031) & (K Pcs)
Table 66. APAC Epidermolysis BullosaTherapeutics Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 67. Europe Epidermolysis BullosaTherapeutics SalesForecast by Country (2026-2031) & (K Pcs)
Table 68. Europe Epidermolysis BullosaTherapeutics RevenueForecast by Country (2026-2031) & ($ millions)
Table 69. Middle East & Africa Epidermolysis BullosaTherapeutics SalesForecast by Country (2026-2031) & (K Pcs)
Table 70. Middle East & Africa Epidermolysis BullosaTherapeutics RevenueForecast by Country (2026-2031) & ($ millions)
Table 71. Global Epidermolysis BullosaTherapeutics SalesForecast byType (2026-2031) & (K Pcs)
Table 72. Global Epidermolysis BullosaTherapeutics RevenueForecast byType (2026-2031) & ($ millions)
Table 73. Global Epidermolysis BullosaTherapeutics SalesForecast by Application (2026-2031) & (K Pcs)
Table 74. Global Epidermolysis BullosaTherapeutics RevenueForecast by Application (2026-2031) & ($ millions)
Table 75. Birken AG Basic Information, Epidermolysis BullosaTherapeutics Manufacturing Base, Sales Area and Its Competitors
Table 76. Birken AG Epidermolysis BullosaTherapeutics Product Portfolios and Specifications
Table 77. Birken AG Epidermolysis BullosaTherapeutics Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 78. Birken AG Main Business
Table 79. Birken AG Latest Developments
Table 80.Fibrocell Science, Inc. Basic Information, Epidermolysis BullosaTherapeutics Manufacturing Base, Sales Area and Its Competitors
Table 81.Fibrocell Science, Inc. Epidermolysis BullosaTherapeutics Product Portfolios and Specifications
Table 82.Fibrocell Science, Inc. Epidermolysis BullosaTherapeutics Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 83.Fibrocell Science, Inc. Main Business
Table 84.Fibrocell Science, Inc. Latest Developments
Table 85. GlaxoSmithKline Plc Basic Information, Epidermolysis BullosaTherapeutics Manufacturing Base, Sales Area and Its Competitors
Table 86. GlaxoSmithKline Plc Epidermolysis BullosaTherapeutics Product Portfolios and Specifications
Table 87. GlaxoSmithKline Plc Epidermolysis BullosaTherapeutics Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 88. GlaxoSmithKline Plc Main Business
Table 89. GlaxoSmithKline Plc Latest Developments
Table 90. InMed Pharmaceuticals Inc. Basic Information, Epidermolysis BullosaTherapeutics Manufacturing Base, Sales Area and Its Competitors
Table 91. InMed Pharmaceuticals Inc. Epidermolysis BullosaTherapeutics Product Portfolios and Specifications
Table 92. InMed Pharmaceuticals Inc. Epidermolysis BullosaTherapeutics Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 93. InMed Pharmaceuticals Inc. Main Business
Table 94. InMed Pharmaceuticals Inc. Latest Developments
Table 95. KarusTherapeutics Limited Basic Information, Epidermolysis BullosaTherapeutics Manufacturing Base, Sales Area and Its Competitors
Table 96. KarusTherapeutics Limited Epidermolysis BullosaTherapeutics Product Portfolios and Specifications
Table 97. KarusTherapeutics Limited Epidermolysis BullosaTherapeutics Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 98. KarusTherapeutics Limited Main Business
Table 99. KarusTherapeutics Limited Latest Developments
Table 100. ProQRTherapeutics N.V. Basic Information, Epidermolysis BullosaTherapeutics Manufacturing Base, Sales Area and Its Competitors
Table 101. ProQRTherapeutics N.V. Epidermolysis BullosaTherapeutics Product Portfolios and Specifications
Table 102. ProQRTherapeutics N.V. Epidermolysis BullosaTherapeutics Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 103. ProQRTherapeutics N.V. Main Business
Table 104. ProQRTherapeutics N.V. Latest Developments
Table 105. RegeneRx Biopharmaceuticals, Inc. Basic Information, Epidermolysis BullosaTherapeutics Manufacturing Base, Sales Area and Its Competitors
Table 106. RegeneRx Biopharmaceuticals, Inc. Epidermolysis BullosaTherapeutics Product Portfolios and Specifications
Table 107. RegeneRx Biopharmaceuticals, Inc. Epidermolysis BullosaTherapeutics Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 108. RegeneRx Biopharmaceuticals, Inc. Main Business
Table 109. RegeneRx Biopharmaceuticals, Inc. Latest Developments
Table 110. Scioderm, Inc. Basic Information, Epidermolysis BullosaTherapeutics Manufacturing Base, Sales Area and Its Competitors
Table 111. Scioderm, Inc. Epidermolysis BullosaTherapeutics Product Portfolios and Specifications
Table 112. Scioderm, Inc. Epidermolysis BullosaTherapeutics Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 113. Scioderm, Inc. Main Business
Table 114. Scioderm, Inc. Latest Developments
Table 115. Stratatech Corporation Basic Information, Epidermolysis BullosaTherapeutics Manufacturing Base, Sales Area and Its Competitors
Table 116. Stratatech Corporation Epidermolysis BullosaTherapeutics Product Portfolios and Specifications
Table 117. Stratatech Corporation Epidermolysis BullosaTherapeutics Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 118. Stratatech Corporation Main Business
Table 119. Stratatech Corporation Latest Developments
Table 120.TWi Pharmaceuticals, Inc. Basic Information, Epidermolysis BullosaTherapeutics Manufacturing Base, Sales Area and Its Competitors
Table 121.TWi Pharmaceuticals, Inc. Epidermolysis BullosaTherapeutics Product Portfolios and Specifications
Table 122.TWi Pharmaceuticals, Inc. Epidermolysis BullosaTherapeutics Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 123.TWi Pharmaceuticals, Inc. Main Business
Table 124.TWi Pharmaceuticals, Inc. Latest Developments
Table 125. WAVE Life Sciences Ltd. Basic Information, Epidermolysis BullosaTherapeutics Manufacturing Base, Sales Area and Its Competitors
Table 126. WAVE Life Sciences Ltd. Epidermolysis BullosaTherapeutics Product Portfolios and Specifications
Table 127. WAVE Life Sciences Ltd. Epidermolysis BullosaTherapeutics Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 128. WAVE Life Sciences Ltd. Main Business
Table 129. WAVE Life Sciences Ltd. Latest Developments



LIST OFFIGURES

Figure 1. Picture of Epidermolysis BullosaTherapeutics
Figure 2. Epidermolysis BullosaTherapeutics Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Epidermolysis BullosaTherapeutics Sales Growth Rate 2020-2031 (K Pcs)
Figure 7. Global Epidermolysis BullosaTherapeutics Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Epidermolysis BullosaTherapeutics Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Epidermolysis BullosaTherapeutics Sales Market Share by Country/Region (2024)
Figure 10. Epidermolysis BullosaTherapeutics Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of EB-201
Figure 12. Product Picture ofFCX-007
Figure 13. Product Picture of ICX-RHY
Figure 14. Product Picture of INM-750
Figure 15. Product Picture of Others
Figure 16. Global Epidermolysis BullosaTherapeutics Sales Market Share byType in 2025
Figure 17. Global Epidermolysis BullosaTherapeutics Revenue Market Share byType (2020-2025)
Figure 18. Epidermolysis BullosaTherapeutics Consumed in Clinic
Figure 19. Global Epidermolysis BullosaTherapeutics Market: Clinic (2020-2025) & (K Pcs)
Figure 20. Epidermolysis BullosaTherapeutics Consumed in Hospital
Figure 21. Global Epidermolysis BullosaTherapeutics Market: Hospital (2020-2025) & (K Pcs)
Figure 22. Epidermolysis BullosaTherapeutics Consumed in Others
Figure 23. Global Epidermolysis BullosaTherapeutics Market: Others (2020-2025) & (K Pcs)
Figure 24. Global Epidermolysis BullosaTherapeutics Sale Market Share by Application (2024)
Figure 25. Global Epidermolysis BullosaTherapeutics Revenue Market Share by Application in 2025
Figure 26. Epidermolysis BullosaTherapeutics Sales by Company in 2025 (K Pcs)
Figure 27. Global Epidermolysis BullosaTherapeutics Sales Market Share by Company in 2025
Figure 28. Epidermolysis BullosaTherapeutics Revenue by Company in 2025 ($ millions)
Figure 29. Global Epidermolysis BullosaTherapeutics Revenue Market Share by Company in 2025
Figure 30. Global Epidermolysis BullosaTherapeutics Sales Market Share by Geographic Region (2020-2025)
Figure 31. Global Epidermolysis BullosaTherapeutics Revenue Market Share by Geographic Region in 2025
Figure 32. Americas Epidermolysis BullosaTherapeutics Sales 2020-2025 (K Pcs)
Figure 33. Americas Epidermolysis BullosaTherapeutics Revenue 2020-2025 ($ millions)
Figure 34. APAC Epidermolysis BullosaTherapeutics Sales 2020-2025 (K Pcs)
Figure 35. APAC Epidermolysis BullosaTherapeutics Revenue 2020-2025 ($ millions)
Figure 36. Europe Epidermolysis BullosaTherapeutics Sales 2020-2025 (K Pcs)
Figure 37. Europe Epidermolysis BullosaTherapeutics Revenue 2020-2025 ($ millions)
Figure 38. Middle East & Africa Epidermolysis BullosaTherapeutics Sales 2020-2025 (K Pcs)
Figure 39. Middle East & Africa Epidermolysis BullosaTherapeutics Revenue 2020-2025 ($ millions)
Figure 40. Americas Epidermolysis BullosaTherapeutics Sales Market Share by Country in 2025
Figure 41. Americas Epidermolysis BullosaTherapeutics Revenue Market Share by Country (2020-2025)
Figure 42. Americas Epidermolysis BullosaTherapeutics Sales Market Share byType (2020-2025)
Figure 43. Americas Epidermolysis BullosaTherapeutics Sales Market Share by Application (2020-2025)
Figure 44. United States Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 ($ millions)
Figure 45. Canada Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 ($ millions)
Figure 46. Mexico Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 ($ millions)
Figure 47. Brazil Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 ($ millions)
Figure 48. APAC Epidermolysis BullosaTherapeutics Sales Market Share by Region in 2025
Figure 49. APAC Epidermolysis BullosaTherapeutics Revenue Market Share by Region (2020-2025)
Figure 50. APAC Epidermolysis BullosaTherapeutics Sales Market Share byType (2020-2025)
Figure 51. APAC Epidermolysis BullosaTherapeutics Sales Market Share by Application (2020-2025)
Figure 52. China Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 ($ millions)
Figure 53. Japan Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 ($ millions)
Figure 54. South Korea Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 ($ millions)
Figure 55. Southeast Asia Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 ($ millions)
Figure 56. India Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 ($ millions)
Figure 57. Australia Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 ($ millions)
Figure 58. ChinaTaiwan Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 ($ millions)
Figure 59. Europe Epidermolysis BullosaTherapeutics Sales Market Share by Country in 2025
Figure 60. Europe Epidermolysis BullosaTherapeutics Revenue Market Share by Country (2020-2025)
Figure 61. Europe Epidermolysis BullosaTherapeutics Sales Market Share byType (2020-2025)
Figure 62. Europe Epidermolysis BullosaTherapeutics Sales Market Share by Application (2020-2025)
Figure 63. Germany Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 ($ millions)
Figure 64.France Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 ($ millions)
Figure 65. UK Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 ($ millions)
Figure 66. Italy Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 ($ millions)
Figure 67. Russia Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 ($ millions)
Figure 68. Middle East & Africa Epidermolysis BullosaTherapeutics Sales Market Share by Country (2020-2025)
Figure 69. Middle East & Africa Epidermolysis BullosaTherapeutics Sales Market Share byType (2020-2025)
Figure 70. Middle East & Africa Epidermolysis BullosaTherapeutics Sales Market Share by Application (2020-2025)
Figure 71. Egypt Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 ($ millions)
Figure 72. South Africa Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 ($ millions)
Figure 73. Israel Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 ($ millions)
Figure 74.Turkey Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 ($ millions)
Figure 75. GCC Countries Epidermolysis BullosaTherapeutics Revenue Growth 2020-2025 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of Epidermolysis BullosaTherapeutics in 2025
Figure 77. Manufacturing Process Analysis of Epidermolysis BullosaTherapeutics
Figure 78. Industry Chain Structure of Epidermolysis BullosaTherapeutics
Figure 79. Channels of Distribution
Figure 80. Global Epidermolysis BullosaTherapeutics Sales MarketForecast by Region (2026-2031)
Figure 81. Global Epidermolysis BullosaTherapeutics Revenue Market ShareForecast by Region (2026-2031)
Figure 82. Global Epidermolysis BullosaTherapeutics Sales Market ShareForecast byType (2026-2031)
Figure 83. Global Epidermolysis BullosaTherapeutics Revenue Market ShareForecast byType (2026-2031)
Figure 84. Global Epidermolysis BullosaTherapeutics Sales Market ShareForecast by Application (2026-2031)
Figure 85. Global Epidermolysis BullosaTherapeutics Revenue Market ShareForecast by Application (2026-2031)